Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage
Genetic mutations cause primary immunodeficiencies (PIDs) that predispose to infections.
Here, we describe activated PI3K-δ syndrome (APDS), a PID associated with a dominant gain-…
Here, we describe activated PI3K-δ syndrome (APDS), a PID associated with a dominant gain-…
[HTML][HTML] Suppl 2: the therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases
E Banham-Hall, MR Clatworthy… - The open rheumatology …, 2012 - ncbi.nlm.nih.gov
The class 1 PI3Ks are lipid kinases with key roles in cell surface receptor-triggered signal
transduction pathways. Two isoforms of the catalytic subunits, p110γ and p110δ, are enriched …
transduction pathways. Two isoforms of the catalytic subunits, p110γ and p110δ, are enriched …
[HTML][HTML] PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner
…, G Bradley, AG Richter, E Banham-Hall… - Nature …, 2018 - nature.com
Streptococcus pneumoniae is a major cause of pneumonia and a leading cause of death
world-wide. Antibody-mediated immune responses can confer protection against repeated …
world-wide. Antibody-mediated immune responses can confer protection against repeated …
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients-mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19–Repurposed Drugs …
S Kulkarni, M Fisk, M Kostapanos, E Banham-Hall… - Trials, 2020 - Springer
Objectives To determine if a specific immunomodulatory intervention reduces progression
of COVID-19-related disease to organ failure or death, compared to standard of care (SoC). …
of COVID-19-related disease to organ failure or death, compared to standard of care (SoC). …
[HTML][HTML] Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial
Background From early in the COVID-19 pandemic, evidence suggested a role for cytokine
dysregulation and complement activation in severe disease. In the TACTIC-R trial, we …
dysregulation and complement activation in severe disease. In the TACTIC-R trial, we …
[HTML][HTML] Cell sorting actuated by a microfluidic inertial vortex
…, ME Bashtanov, RD Gold, A Hailes, E Banham-Hall… - Lab on a Chip, 2019 - pubs.rsc.org
The sorting of specific cell populations is an established tool in biological research, with
new applications demanding greater cell throughput, sterility and elimination of cross-…
new applications demanding greater cell throughput, sterility and elimination of cross-…
[HTML][HTML] An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of activated PI3 kinase delta syndrome
M Begg, A Amour, E Jarvis, T Tang, SS Franco… - Pulmonary …, 2023 - Elsevier
Activated PI3Kδ Syndrome (APDS) is a rare inherited inborn error of immunity caused by
mutations that constitutively activate the p110 delta isoform of phosphoinositide 3-kinase (PI3Kδ…
mutations that constitutively activate the p110 delta isoform of phosphoinositide 3-kinase (PI3Kδ…
[HTML][HTML] muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): a structured summary of a study …
…, S Kulkarni, M Fisk, M Kostapanos, E Banham-Hall… - Trials, 2020 - Springer
Objectives To determine if a specific intervention reduces the composite of progression of
patients with COVID-19-related disease to organ failure or death as measured by time to …
patients with COVID-19-related disease to organ failure or death as measured by time to …
[HTML][HTML] Hindsight bias critically impacts on clinicians' assessment of care quality in retrospective case note review
E Banham-Hall, S Stevens - Clinical Medicine, 2019 - ncbi.nlm.nih.gov
Objective. To determine whether hindsight bias impacts on retrospective case note review
using a five point scoring system based on modern clinical governance toolkits. Design. …
using a five point scoring system based on modern clinical governance toolkits. Design. …
Safety, tolerability, and pharmacokinetics of a new formulation of nemiralisib administered via a dry powder inhaler to healthy individuals
…, C Leemereise, R Eames, E Banham-Hall… - Clinical Therapeutics, 2019 - Elsevier
Purpose Nemiralisib, a phosphoinositide 3-kinase δ inhibitor, is being investigated as an
immunomodulatory agent with anti-inflammatory properties in chronic obstructive pulmonary …
immunomodulatory agent with anti-inflammatory properties in chronic obstructive pulmonary …